India, Aug. 14 -- Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update.
Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. Its lead programs include fasedienol for social anxiety disorder, itruvone for major depressive disorder and refisolone for menopausal hot flashes.
First Quarter Highlights
For the first quarter ended June 30, 2026, net loss narrowed to $13.0 million or $0.30 per share from $15.1 million or $0.47 per share in the year-ago quarter.
Revenue was $1.2 million, primar...